Another abrupt departure of a high ranking Food and Drug Administration (FDA) official is raising alarm about a brain drain that could mean new drugs take longer to reach the public. The stakes are enormous for both pharmaceutical companies spending huge sums developing new treatments and the American public counting on the agency to ensure […]

The postFDA faces brain drain as 4th director exits roleappeared first onRolling Out.